

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III FLAURA2 trial evaluating osimertinib combined with chemotherapy versus osimertinib alone for patients with previously untreated EGFR-mutant non-small cell lung cancer (NSCLC) reported which of the following efficacy outcomes with the combination?**

 - Inferior overall survival (OS)
 - A numerical but nonsignificant increase in OS
 - A significant increase in OS**
- 2. The Phase III MARIPOSA trial evaluating amivantamab with lazertinib versus osimertinib monotherapy in the front-line setting for patients with EGFR-mutant locally advanced or metastatic NSCLC reported which of the following efficacy outcomes with amivantamab and lazertinib?**

 - No significant difference in OS in high-risk subgroups
 - A statistically significant improvement in OS in the all-comers population**
 - A statistically significant improvement in OS in high-risk subgroups only
 - Inferior OS in the all-comers population
- 3. The ongoing Phase III TROPION-Lung15 trial is evaluating which of the following regimens versus platinum-based chemotherapy for patients with EGFR-mutant advanced NSCLC who previously experienced disease progression on osimertinib?**

 - Amivantamab with or without lazertinib
 - Datopotamab deruxtecan with or without osimertinib**
 - Zipalertinib with or without chemotherapy
 - Sunvozertinib with or without chemotherapy
- 4. Which of the following side effects is a notable any-grade adverse event experienced by most patients receiving sacituzumab tirumotecan in the OptiTROP-Lung04 study?**

 - Hypokalemia
 - Diarrhea
 - Rash
 - Stomatitis**
- 5. The Phase IIb REZILIENT1 study evaluating zipalertinib for patients with previously treated advanced NSCLC and an EGFR exon 20 insertion reported which confirmed objective response rate in the primary efficacy population?**

 - 22%
 - 35%**
 - 54%
 - 68%